ESR1 and breast carcinoma: Since we and others have reported that PKCα expression can be a predictive marker of TAM resistance[2-4] our T47D:A18/PKCα model suggests that detection of extranuclear ERα can be used to monitor therapeutic response in TAM-resistant, PKCα-expressing breast cancers.